For many UK employers, pre-employment drug screening remains associated with heavy industry, aviation or transport rather than mainstream recruitment. Unlike the United States, where workplace drug testing has been commonplace for decades, the UK has traditionally taken a more measured and proportionate approach. But is that starting to change? asks Melissa Sorenson, pictured, Executive Director of Professional Background Screening Association (PBSA).
As organisations face growing concerns around workplace safety, employee wellbeing, regulatory compliance and reputational risk, drug and alcohol testing is becoming part of a wider conversation about workforce compliance. While the UK is unlikely to mirror the widespread testing culture seen in America, the issue is becoming increasingly relevant for UK employers.
The biggest difference between the two countries lies in their approach. In the US, pre-employment drug testing has long been a familiar element of hiring. Federally regulated industries such as aviation, rail and commercial transport require structured testing programmes, while many private employers have historically adopted screening as routine practice.
UK distinction
The UK has taken a different path. With the exception of some regulated industries, there is no general legal requirement for employers to conduct pre-employment drug testing. Instead, testing must be necessary, proportionate and justified by the risks associated with the role.
As my PBSA colleague Job van der Weijden, Managing Director, Europe at DISA Global Solutions, explains: “There is no UK-wide data showing a general increase in employer drug testing, but we are seeing greater testing activity within safety-critical workforces. The shift is less about expanding pre-employment screening and more about ongoing fitness-for-work testing, particularly across transport, infrastructure, construction, nuclear, energy and logistics. Importantly, these requirements can also flow down through supply chains to contractors and suppliers, significantly widening their reach.”
That distinction matters. Testing should never become a tick-box exercise added indiscriminately to recruitment. It should be based on a considered assessment of the responsibilities and risks associated with particular roles.
At the same time, the conversation is broadening beyond illicit drug use. Alcohol, prescription medication and other substances that could affect an individual’s ability to perform safely are increasingly part of the equation. Testing is therefore becoming less about simply identifying illegal drug use and more about managing fitness for work, workplace safety and responsible governance.
Interestingly, the future may see the US moving closer to the UK approach rather than the other way around. A growing number of American states are restricting employers’ reliance on traditional cannabis testing, particularly where results indicate historic use rather than current impairment. This is encouraging greater focus on whether someone is fit to perform their role safely rather than simply whether traces of a substance can be detected.
HR policy
For multinational employers, this creates another challenge. Europe is not a single market when it comes to employment screening. While overarching regulations such as the EU General Data Protection Regulation (GDPR) provide a common framework, domestic laws governing personal data, employment practices and workplace testing vary considerably between jurisdictions. Cultural attitudes and accepted practices also differ, making a one-size-fits-all global policy difficult to apply. Employers therefore need a consistent screening framework that can be adapted to the legal requirements, accepted practices and risk profile of each country in which they operate.
For HR leaders, this starts with having a robust HR policy, supported by a clear screening policy that sets out the purpose and necessity of testing. It should define which roles justify testing, why it is necessary and proportionate, when it will take place and how results will be managed, while ensuring compliance with privacy laws. Where appropriate, non-negative results should be reviewed by a Medical Review Officer (MRO), who can consider legitimate medical explanations before a final employment decision is made.
Methodology
Methodology matters too. Different testing methods provide different information and detection windows. Employers should therefore start with the risk they are trying to manage and select an approach appropriate to that purpose, without collecting more information than necessary. The methodology chosen can also affect how practical ongoing or random testing is across large or dispersed workforces.
Crucially, a positive result should rarely be viewed in isolation. The presence of a substance does not necessarily demonstrate impairment, making context, professional judgement and fairness essential. Nor should the conversation stop once someone is hired. A pre-employment test provides only a point-in-time assessment and cannot offer continuing assurance throughout employment. In safety-critical environments, where justified by risk, targeted random or periodic testing can form part of a wider fitness-for-work programme alongside medication declarations, occupational health reviews and return-to-work assessments.
For screening partners, this means helping employers look beyond the initial hire and develop proportionate, role-based approaches that reflect workforce risk and differing legal requirements across jurisdictions.
Ultimately, the future is unlikely to be blanket drug and alcohol testing across every industry. Instead, the direction is towards intelligent, risk-based workforce screening that balances safety, individual fairness and organisational responsibility. Here in the UK, the question is no longer simply whether to test. It is whether policies are sophisticated enough to determine who should be tested, when, why and how and whether a one-off pre-employment check is really enough.
